Moderna Inc
MRNA: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|m> | LOCK|CyS | LOCK|&%sH#& |
Moderna: Analyst Day Supports Our Bullish Oncology Call; Pruned Pipeline Helps Conserve Cash
Moderna held an analyst day on Nov. 20, where it made several announcements, including a new $1.5 billion credit facility, expectations for up to 10% revenue growth in 2026, improving gross margins through 2028, and discontinuations of midstage shingles and herpes programs. Shares fell 7%.
